XORTX Therapeutics Inc.
Sağlık
UYGUN DEĞİL — Bir veya daha fazla oran eşiği aşıyor; şirket helal yatırım kriterlerine uygun değildir.
$0.93
Fiyat (1 Yıl)
Katılım Finansı Tarama Oranları
Oranlar AAOIFI tabanlı tarama dosyasından alınmıştır; fetva niteliği taşımaz.
Şirket Hakkında
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney.
Web SitesiXRTX Hissesi Caiz mi, Helal mi? XORTX Therapeutics Inc. Katılım Analizi